NSABP B 23--SHORT INTENSIVE AC W/WO TAMOXIFEN W/ CONVENTIONAL CMF

目前正在进行的这项研究是为了确定是否 阿霉素和环磷酰胺联合或不联合他莫昔芬治疗4个周期 比使用环磷酰胺、甲氨蝶呤和 5-氟尿嘧啶联合或不联合他莫昔芬治疗6个周期。有结节的女性- 阴性乳腺癌和病理肿块大小<1.0 cm者 接受肿块切除或全乳房切除和腋窝清扫术 经检测其肿瘤雌激素受体为-lt；10 通过葡聚糖包被的木炭或蔗糖- 密度梯度法，或用酶免疫法测定15fmol/mg 方法将符合条件。如果使用免疫细胞化学方法(ER-ICA) 并被报告为阴性，也将是可以接受的。某种形式的 必须进行孕激素受体分析，结果是 已提交。黄体酮分析可包括定量或定性 (PR-ICA)方法。患者将按年龄、临床肿瘤进行分层 规模和操作类型。

The current study is being conducted to determine whether administering Adriamycin and Cyclophosphamide with or without tamoxifen for four cycles is more effective than administering cyclophosphamide, methotrexate, and 5-fluorouracil for six cycles with or without tamoxifen. Women with node- negative breast cancer and pathological tumor size > 1.0 cm who have undergone lumpectomy or total mastectomy and axillary dissection and whose tumor estrogen receptors have been assayed and found to be < 10 fmol/mg cytosol protein by either the dextran-coated charcoal or sucrose- density gradient methods, or < 15 fmol/mg by the enzyme immunoassay method will be eligible. If the immunocytochemical assay (ER-ICA) is used and is reported as negative, it will also be acceptable. Some form of progesterone-receptor analysis must be perfomred and the results submitted. Progesterone analysis may include quantitative or qualitative (PR-ICA) methods. Patients will be stratified by age, clinical tumor size, and type of operation.